Clinical Trial

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Study acronym: CHIMERA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-10.
Trial Details
NCT Number NCT07407465
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Collaborators: AstraZeneca
Conditions Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer, Metastatic, Colon Cancer Metastatic, Colon Cancer Adenocarcinoma
Enrollment 42 participants
Start Date 2025-10-20
Primary Completion 2027-10-20 (estimated)
Study Completion 2027-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-02-17